Table 1 Patient characteristics
Characteristics | Total group (N = 135) [IQR], (%) | Early-stage (N = 113) [IQR], (%) | Advanced-stage (N = 22) [IQR], (%) |
|---|---|---|---|
Age (years) | 54 [47–61] | 53 [47–60] | 61 [53–65] |
BMI (kg/m2) | 25.6 [23.7–29.5] | 25.6 [23.6–29.4] | 26.1 [23.9–30.1] |
Duration of trastuzumab treatment (months) | 11 [11–12] | 11 [11–11] | 16 [9–44] |
Pretreatment with anthracycline (doxorubicin) | 111 (82) | 107 (95) | 4 (18) |
Local radiotherapy | 61 (45) | 53 (47) | 8 (36) |
Cardiac condition before treatment | |||
• Valve insufficiency | 5 (3.5) | 3 (2.6) | 2 (9) |
• Arrhythmia | 5 (3.7) | 4 (3.5%) | 1 (4.5) |
• MI/CABG/PCI | 0 | 0 | 0 |
LVEF (%) | 62 [58–65] | 62 [58–65]a | 61 [57–66]b |
NT-proBNP (pmol/l)c | 9 [5–14] | 8 [5–14] | 11 [7–18] |
Follow-up duration (months)d | 13 [11–14] | 13 [11–14] | 11 [9–12] |